Karen L. Goldenthal

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Lisa M. Dunkle, Ruvim Izikson, P. Patriarca et al. · New England Journal of Medicine · 2017 · 286 citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Developing New Smallpox Vaccines

Michael Merchlinsky, Cynthia Kleppinger, Karen L. Goldenthal · Emerging infectious diseases · 2001 · 139 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

Roger Baxter, P. Patriarca, Kathleen Ensor et al. · Vaccine · 2011 · 109 citations

Veterinary Medicine, Immunology, Infectious Diseases +13

Postfixation detergent treatment for immunofluorescence suppresses localization of some integral membrane proteins.

Karen L. Goldenthal, Klaus Hedman, J W Chen et al. · Journal of Histochemistry & Cytochemistry · 1985 · 106 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant

John J. Treanor, Brandon Essink, Steven Hull et al. · Vaccine · 2013 · 85 citations

Pharmacy, Immunology, Pharmaceutics +16